Bridgeway Capital Management’s Marker Therapeutics MRKR Stock Holding History

Bridgeway Capital Management’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-24,922	Closed	-$92K	–	1426
2022 Q3	$92K	Hold	24,922	–	–	﹤0.01%	1290
2022 Q2	$82K	Sell	24,922 -7,500	-23%	-$24.9K	﹤0.01%	1248
2022 Q1	$143K	Hold	32,422	–	–	﹤0.01%	1226
2021 Q4	$308K	Buy	32,422 +3,500	+12%	+$46.5K	0.01%	1097
2021 Q3	$489K	Buy	28,922 +12,700	+78%	+$260K	0.01%	1035
2021 Q2	$453K	Sell	16,222 -2,885	-15%	-$76K	0.01%	1093
2021 Q1	$428K	Sell	19,107 -715	-4%	-$16.4K	0.01%	1133
2020 Q4	$287K	Sell	19,822 -2,500	-11%	-$38.8K	0.01%	1129
2020 Q3	$335K	Hold	22,322	–	–	0.01%	1027
2020 Q2	$462K	Buy	+22,322	New	+$488K	0.01%	884

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MAA

Matrix Asset Advisors White Plains, New York $1.23B AUM 26.4% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bridgeway Capital Management's MRKR Position: Q4 2022 in Review

Bridgeway Capital Management sold out of Marker Therapeutics (MRKR) in Q4 2022, closing a stake of 24,922 shares — an estimated $92K sold.

Bridgeway Capital Management first reported a position in MRKR in Q2 2020 and held it in 10 quarters. The position peaked at $489K in Q3 2021. 47 funds tracked by Wall St. Rank hold MRKR as of Q4 2022.

Bridgeway Capital Management reported no remaining Marker Therapeutics position as of Q4 2022 after selling out during the quarter.
Bridgeway Capital Management sold 24,922 Marker Therapeutics shares in Q4 2022, an estimated $92K.
Bridgeway Capital Management first reported a position in Marker Therapeutics in Q2 2020 and held it in 10 quarters.
Bridgeway Capital Management's Marker Therapeutics position peaked at $489K in Q3 2021.
47 funds tracked by Wall St. Rank held Marker Therapeutics as of Q4 2022.

Based on Bridgeway Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.